FibroGen, Inc (FGEN): Price and Financial Metrics


FibroGen, Inc (FGEN): $11.40

0.84 (+7.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FGEN POWR Grades


  • Value is the dimension where FGEN ranks best; there it ranks ahead of 73.3% of US stocks.
  • FGEN's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • FGEN ranks lowest in Stability; there it ranks in the 11th percentile.

FGEN Stock Summary

  • Of note is the ratio of Fibrogen Inc's sales and general administrative expense to its total operating expenses; merely 10.35% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 187.64%, Fibrogen Inc's debt growth rate surpasses 94.09% of about US stocks.
  • In terms of volatility of its share price, FGEN is more volatile than 82.14% of stocks we're observing.
  • Stocks that are quantitatively similar to FGEN, based on their financial statements, market capitalization, and price volatility, are ORMP, KLDO, RAPT, ATRA, and APTX.
  • FGEN's SEC filings can be seen here. And to visit Fibrogen Inc's official web site, go to www.fibrogen.com.

FGEN Valuation Summary

  • In comparison to the median Healthcare stock, FGEN's price/sales ratio is 44.49% lower, now standing at 6.3.
  • FGEN's EV/EBIT ratio has moved up 43.1 over the prior 83 months.
  • Over the past 83 months, FGEN's price/earnings ratio has gone up 29.6.

Below are key valuation metrics over time for FGEN.

Stock Date P/S P/B P/E EV/EBIT
FGEN 2021-08-31 6.3 4.1 -4.7 -3.6
FGEN 2021-08-30 6.2 4.1 -4.6 -3.6
FGEN 2021-08-27 6.2 4.1 -4.6 -3.6
FGEN 2021-08-26 6.2 4.1 -4.6 -3.5
FGEN 2021-08-25 6.4 4.2 -4.8 -3.7
FGEN 2021-08-24 6.5 4.3 -4.8 -3.8

FGEN Growth Metrics

    Its year over year cash and equivalents growth rate is now at 256.62%.
  • The 4 year net income to common stockholders growth rate now stands at -63.42%.
  • Its year over year net cashflow from operations growth rate is now at 159.81%.
Over the past 15 months, FGEN's revenue has gone up $116,014,000.

The table below shows FGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 235.309 -82.232 -290.023
2021-12-31 235.309 -82.232 -290.023
2021-09-30 283.765 -34.5 -214.579
2021-06-30 171.824 -80.104 -231.373
2021-03-31 190.348 96.104 -182.698
2020-12-31 176.319 81.602 -189.291

FGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FGEN has a Quality Grade of B, ranking ahead of 75.49% of graded US stocks.
  • FGEN's asset turnover comes in at 0.212 -- ranking 192nd of 681 Pharmaceutical Products stocks.
  • CKPT, ARWR, and IBIO are the stocks whose asset turnover ratios are most correlated with FGEN.

The table below shows FGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.212 0.934 -1.182
2021-03-31 0.235 0.941 -0.907
2020-12-31 0.216 0.950 -0.594
2020-09-30 0.145 0.940 -0.473
2020-06-30 0.128 0.952 -0.520
2020-03-31 0.295 0.992 -0.151

FGEN Price Target

For more insight on analysts targets of FGEN, see our FGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.71 Average Broker Recommendation 1.9 (Hold)

FGEN Stock Price Chart Interactive Chart >

Price chart for FGEN

FGEN Price/Volume Stats

Current price $11.40 52-week high $27.55
Prev. close $10.56 52-week low $7.81
Day low $10.49 Volume 751,700
Day high $11.55 Avg. volume 918,559
50-day MA $9.77 Dividend yield N/A
200-day MA $12.13 Market Cap 1.06B

FibroGen, Inc (FGEN) Company Bio


Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.


FGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream


Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about Fibrogen Inc that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the F

Yahoo | February 14, 2022

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST.

GlobeNewswire | February 4, 2022

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days. About FibroGen Fibro

Yahoo | February 4, 2022

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo 14.11%
3-mo -12.04%
6-mo -20.67%
1-year -57.21%
3-year -74.30%
5-year -65.14%
YTD -19.15%
2021 -61.98%
2020 -13.52%
2019 -7.32%
2018 -2.36%
2017 121.50%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5371 seconds.